BioLargo (NASDAQ:BLGO – Get Free Report) is one of 32 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.
Profitability
This table compares BioLargo and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -591.84% | 5.15% | -0.65% |
Insider & Institutional Ownership
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 70.6% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by insiders. Comparatively, 10.6% of shares of all “Chemicals & allied products” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.16 |
BioLargo Competitors | $6.84 billion | $211.64 million | 69.50 |
BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
BioLargo has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, suggesting that their average share price is 81% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for BioLargo and its peers, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1251 | 1567 | 44 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 13.55%. Given BioLargo’s peers higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.
Summary
BioLargo peers beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.